Analysts See $-0.77 EPS for Summit Therapeutics plc (SMMT)

March 7, 2018 - By Peter Erickson

 Analysts See $ 0.77 EPS for Summit Therapeutics plc (SMMT)

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.77 EPS on April, 4.They anticipate $0.27 EPS change or 54.00 % from last quarter’s $-0.5 EPS. After having $-0.20 EPS previously, Summit Therapeutics plc’s analysts see 285.00 % EPS growth. The stock increased 5.43% or $0.69 during the last trading session, reaching $13.4. About 61,473 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since March 8, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 8 analysts covering Summit Therapeutic (NASDAQ:SMMT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Summit Therapeutic had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Friday, September 16. The stock has “Hold” rating by Zacks on Tuesday, September 1. The rating was initiated by Janney Capital on Tuesday, June 21 with “Buy”. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) on Wednesday, August 19 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, July 6. On Friday, January 26 the stock rating was maintained by Oppenheimer with “Outperform”. As per Friday, December 1, the company rating was reinitiated by H.C. Wainwright. Canaccord Genuity maintained Summit Therapeutics plc (NASDAQ:SMMT) on Thursday, June 15 with “Buy” rating. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, November 16. The firm earned “Buy” rating on Thursday, June 22 by Oppenheimer.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $190.19 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: which released: “Summit Therapeutics PLC ADR” on June 26, 2016. Also published the news titled: “Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta” on October 04, 2016.‘s news article titled: “Summit Therapeutics PLC ADR SMMT (US: Nasdaq)” with publication date: February 13, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: